Cooperative Agreement U01IP001191

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to assess the impact of influenza vaccination during pregnancy on maternal disease severity, infant growth outcomes, and the cost-effectiveness of vaccination timing strategies in rural Nepal. The $320,788 award will leverage data from a previous maternal influenza vaccine clinical trial to: 1) Evaluate the effect of...

The federal Cooperative Agreement award U01IP001257, valued at $19,786,074.00 and awarded by the National Center for Immunization and Respiratory Diseases (NCIRD) of the Centers for Disease Control and Prevention (CDC), will fund a 5-year prospective observational study of respiratory virus epidemiology in the greater Boston area. This grant is awarded under the CDC's Public Health Emergency Response: Cooperative Agreement for Emergency Response (CFDA 93.354) program, which supports state,...

This $175,000 Project Grant awarded by the National Science Foundation (NSF) Biological Sciences program (CFDA 47.074) will develop new computational models and forecasting approaches to predict the incidence and severity of respiratory illnesses like COVID-19, influenza, and RSV for the 2024-2025 season. The project aims to combine computational modeling with human judgment to improve the accuracy and responsiveness of public health forecasting on a national scale. It will deliver weekly...

This $195,101 Project Grant, awarded by the National Science Foundation's (NSF) Biological Sciences program (CFDA 47.074), will use mathematical modeling to project the healthcare burden associated with COVID-19, influenza, and respiratory syncytial virus (RSV) in the United States during the 2023-2024 respiratory virus season. The research will integrate estimates of population immunity from prior infections, vaccinations, and monoclonal antibody therapy to produce four rounds of projections...

The U.S. Centers for Disease Control and Prevention (CDC) awarded a $12,107,589 cooperative agreement to the University of Washington (UW) on August 1, 2024 under the Strengthening Public Health through Surveillance, Epidemiologic Research, Disease Detection and Prevention program (CFDA 93.326). This 5-year award, titled "SEAPREP: SEATTLE PANDEMIC PREPAREDNESS COHORT", will support UW in conducting comprehensive public health research and capacity-building initiatives focused on...

This Cooperative Agreement award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to develop computational models that can accurately predict the breadth and durability of influenza vaccine-induced immunity. The key objectives are to: 1) capture existing influenza vaccine data and generate new experimental data connecting immune variables to vaccine outcomes; 2) generate...

This $15,981,588 project grant from the National Institutes of Health's National Institute of Allergy and Infectious Diseases aims to develop pan-coronavirus vaccines. Led by Washington University, the collaborative program includes eleven laboratories seeking to design optimized B and T cell antigens conferring broad immunity against sarbecoviruses and merbecoviruses. The three-year award beginning September 2022 supports three integrated research projects and two centralized cores. Project 1...

The University of Washington was awarded a $41,075,241 Cooperative Agreement from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) to develop end-to-end strategies for pandemic preparedness vaccine development, with a focus on Bunyaviruses and Paramyxoviruses. The project will apply machine learning-enabled computational methods for vaccine and antibody design, coupled with fundamental research on viral entry, antigen design,...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $974,325.00 to support research on the impact of mucosal adjuvanted vaccines on virus transmission in preclinical animal models for SARS-CoV-2 and influenza. The key objectives of this research project are to: 1) compare the protective immune responses and impact on virus transmission provided by intranasal...

This $446,876 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports a comprehensive spatial sequencing study of age-induced changes in the lung during influenza infection. Researchers at Northwestern University will utilize advanced techniques like single-cell RNA sequencing and spatial sequencing to generate a high-resolution atlas of young and aged lung tissue following...